EULAR: Routine, proactive therapeutic drug monitoring unnecessary in RMDs

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.“Understanding whether [therapeutic drug monitoring (TDM)] would improve ownership of patient health decisions is important,” Charlotte L.M. Krieckaert, MD, of the Amsterdam Rheumatology and Immunology Center, and co-authors wrote in the Annals of the Rheumatic Diseases. “Equally, many rheumatologists are unaware of the pharmacokinetic properties of biopharmaceuticals andRead More